# Cue Biopharma, Inc.: financial statements, quarterly

CUE · Nasdaq · CIK 1645460 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cue.md) · [Financials](/companies/cue/financials.md) · [Filings](/companies/cue/filings.md) · [Insiders](/companies/cue/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cue/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2.1](/filings/0000950170-24-127005.md) | [1.8 d](/filings/0000950170-25-047677.md) | [1.7](/filings/0000950170-25-069125.md) | [2.7](/filings/0000950170-25-107270.md) | [3.3](/filings/0001193125-25-277466.md) | [1.6 d](/filings/0001193125-26-108287.md) | [0.4](/filings/0001193125-26-224091.md) | [3.0](/filings/0001193125-26-352128.md) | [2.1](/filings/0001193125-25-277466.md) | [21.9 d](/filings/0001193125-26-108287.md) | [5.7](/filings/0001193125-26-224091.md) | [7.9](/filings/0001193125-26-352128.md) |
| Research and development | $m | [9.9](/filings/0000950170-24-127005.md) | [10.9 d](/filings/0000950170-25-047677.md) | [10.2](/filings/0000950170-25-069125.md) | [9.5](/filings/0000950170-25-107270.md) | [9.4](/filings/0001193125-25-277466.md) | [7.2 d](/filings/0001193125-26-108287.md) | [8.5](/filings/0001193125-26-224091.md) | [7.9](/filings/0001193125-26-352128.md) | [4.8](/filings/0001193125-25-277466.md) | [16.5 d](/filings/0001193125-26-108287.md) | [6.9](/filings/0001193125-26-224091.md) | [49.0](/filings/0001193125-26-352128.md) |
| Operating income | $m | [(11.4)](/filings/0000950170-24-127005.md) | [(13.8) d](/filings/0000950170-25-047677.md) | [(12.7)](/filings/0000950170-25-069125.md) | [(10.4)](/filings/0000950170-25-107270.md) | [(8.8)](/filings/0001193125-25-277466.md) | [(9.6) d](/filings/0001193125-26-108287.md) | [(12.3)](/filings/0001193125-26-224091.md) | [(8.6)](/filings/0001193125-26-352128.md) | [(7.6)](/filings/0001193125-25-277466.md) | [2.0 d](/filings/0001193125-26-108287.md) | [(5.4)](/filings/0001193125-26-224091.md) | [(87.7)](/filings/0001193125-26-352128.md) |
| Interest expense | $m | [0.3](/filings/0000950170-23-058838.md) | [(0.7) d](/filings/0000950170-25-047677.md) | [0.0](/filings/0000950170-24-056838.md) | not reported | not reported | not reported | [0.1](/filings/0001193125-26-224091.md) | [0.0](/filings/0001193125-26-352128.md) | not reported | not reported | not reported | not reported |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(11.0)](/filings/0000950170-24-127005.md) | [(13.4) d](/filings/0000950170-25-047677.md) | [(12.3)](/filings/0000950170-25-069125.md) | [(10.2)](/filings/0000950170-25-107270.md) | [(8.7)](/filings/0001193125-25-277466.md) | [(9.5) d](/filings/0001193125-26-108287.md) | [(12.3)](/filings/0001193125-26-224091.md) | [(8.5)](/filings/0001193125-26-352128.md) | [(7.4)](/filings/0001193125-25-277466.md) | [1.6 d](/filings/0001193125-26-108287.md) | [(5.2)](/filings/0001193125-26-224091.md) | [(153)](/filings/0001193125-26-352128.md) |
| Diluted EPS | $ per share | [(0.24)](/filings/0000950170-24-127005.md) | not reported | [(0.25)](/filings/0000950170-25-069125.md) | [(0.20)](/filings/0000950170-25-107270.md) | [(0.17)](/filings/0001193125-25-277466.md) | not reported | [(4.95)](/filings/0001193125-26-224091.md) | [(2.67)](/filings/0001193125-26-352128.md) | [(0.07)](/filings/0001193125-25-277466.md) | not reported | [(1.08)](/filings/0001193125-26-224091.md) | [(24.14)](/filings/0001193125-26-352128.md) |
| Basic EPS | $ per share | [(0.24)](/filings/0000950170-24-127005.md) | not reported | [(0.25)](/filings/0000950170-25-069125.md) | [(0.20)](/filings/0000950170-25-107270.md) | [(0.17)](/filings/0001193125-25-277466.md) | not reported | [(4.95)](/filings/0001193125-26-224091.md) | [(2.67)](/filings/0001193125-26-352128.md) | [(0.07)](/filings/0001193125-25-277466.md) | not reported | [(1.08)](/filings/0001193125-26-224091.md) | [(24.14)](/filings/0001193125-26-352128.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [54.7](/filings/0000950170-23-058838.md) | [48.5](/filings/0000950170-25-047677.md) | [41.0](/filings/0000950170-24-056838.md) | [30.0](/filings/0000950170-24-096967.md) | [32.4](/filings/0000950170-24-127005.md) | [22.5](/filings/0001193125-26-108287.md) | [13.1](/filings/0000950170-25-069125.md) | [27.5](/filings/0000950170-25-107270.md) | [11.7](/filings/0001193125-25-277466.md) | [27.1](/filings/0001193125-26-352128.md) | [16.4](/filings/0001193125-26-224091.md) | [17.4](/filings/0001193125-26-352128.md) |
| Current assets | $m | [57.5](/filings/0000950170-23-058838.md) | [51.5](/filings/0000950170-25-047677.md) | [44.7](/filings/0000950170-24-056838.md) | [33.9](/filings/0000950170-24-096967.md) | [37.3](/filings/0000950170-24-127005.md) | [25.1](/filings/0001193125-26-108287.md) | [15.9](/filings/0000950170-25-069125.md) | [30.8](/filings/0000950170-25-107270.md) | [25.8](/filings/0001193125-25-277466.md) | [37.0](/filings/0001193125-26-352128.md) | [26.4](/filings/0001193125-26-224091.md) | [26.6](/filings/0001193125-26-352128.md) |
| Total assets | $m | [68.9](/filings/0000950170-23-058838.md) | [61.5](/filings/0000950170-25-047677.md) | [54.0](/filings/0000950170-24-056838.md) | [42.3](/filings/0000950170-24-096967.md) | [44.8](/filings/0000950170-24-127005.md) | [32.2](/filings/0001193125-26-108287.md) | [22.3](/filings/0000950170-25-069125.md) | [40.7](/filings/0000950170-25-107270.md) | [31.6](/filings/0001193125-25-277466.md) | [42.2](/filings/0001193125-26-352128.md) | [30.9](/filings/0001193125-26-224091.md) | [30.7](/filings/0001193125-26-352128.md) |
| Current liabilities | $m | [17.2](/filings/0000950170-23-058838.md) | [17.1](/filings/0000950170-25-047677.md) | [18.1](/filings/0000950170-24-056838.md) | [16.5](/filings/0000950170-24-096967.md) | [16.8](/filings/0000950170-24-127005.md) | [13.7](/filings/0001193125-26-108287.md) | [15.5](/filings/0000950170-25-069125.md) | [19.3](/filings/0000950170-25-107270.md) | [15.5](/filings/0001193125-25-277466.md) | [13.5](/filings/0001193125-26-352128.md) | [7.4](/filings/0001193125-26-224091.md) | [21.2](/filings/0001193125-26-352128.md) |
| Total liabilities | $m | [26.2](/filings/0000950170-23-058838.md) | [24.4](/filings/0000950170-25-047677.md) | [23.9](/filings/0000950170-24-056838.md) | [20.7](/filings/0000950170-24-096967.md) | [19.4](/filings/0000950170-24-127005.md) | [14.7](/filings/0001193125-26-108287.md) | [15.7](/filings/0000950170-25-069125.md) | [22.5](/filings/0000950170-25-107270.md) | [18.4](/filings/0001193125-25-277466.md) | [15.8](/filings/0001193125-26-352128.md) | [9.3](/filings/0001193125-26-224091.md) | [28.4](/filings/0001193125-26-352128.md) |
| Long-term debt | $m | [5.2](/filings/0000950170-23-058838.md) | [4.2](/filings/0000950170-25-047677.md) | [3.2](/filings/0000950170-24-056838.md) | [2.3](/filings/0000950170-24-096967.md) | [1.3](/filings/0000950170-24-127005.md) | [0.0](/filings/0000950170-25-047677.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | [4.0](/filings/0000950170-23-058838.md) | [4.0](/filings/0000950170-24-038059.md) | [4.0](/filings/0000950170-24-056838.md) | [4.0](/filings/0000950170-24-096967.md) | [4.0](/filings/0000950170-24-127005.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | [0.0](/filings/0000950170-24-038059.md) | [0.0](/filings/0000950170-24-056838.md) | not reported | not reported | [0.0](/filings/0000950170-25-047677.md) | [0.1](/filings/0000950170-25-069125.md) | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [42.7](/filings/0000950170-24-127005.md) | [37.1](/filings/0001193125-26-108287.md) | [30.0](/filings/0000950170-25-107270.md) | [21.6](/filings/0001193125-25-277466.md) | [25.4](/filings/0001193125-25-277466.md) | [17.5](/filings/0001193125-26-352128.md) | [6.6](/filings/0001193125-26-352128.md) | [18.2](/filings/0001193125-26-352128.md) | [13.2](/filings/0001193125-25-277466.md) | [26.4](/filings/0001193125-26-352128.md) | [21.6](/filings/0001193125-26-352128.md) | [2.3](/filings/0001193125-26-352128.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(7.8) d](/filings/0000950170-24-127005.md) | [(11.0) d](/filings/0000950170-25-047677.md) | [(9.8)](/filings/0000950170-25-069125.md) | [(10.0) d](/filings/0000950170-25-107270.md) | [(7.5) d](/filings/0001193125-25-277466.md) | [(9.0) d](/filings/0001193125-26-108287.md) | [(8.2)](/filings/0001193125-26-224091.md) | [(3.4) d](/filings/0001193125-26-352128.md) | [(9.0) d](/filings/0001193125-25-277466.md) | [(1.1) d](/filings/0001193125-26-108287.md) | [(10.9)](/filings/0001193125-26-224091.md) | [(29.0) d](/filings/0001193125-26-352128.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-24-127005.md) | [0.0 d](/filings/0000950170-25-047677.md) | [0.1](/filings/0000950170-25-069125.md) | [0.0 d](/filings/0000950170-25-107270.md) | [(0.0) d](/filings/0001193125-25-277466.md) | [0.0 d](/filings/0001193125-26-108287.md) | [0.2](/filings/0001193125-26-224091.md) | [0.0 d](/filings/0001193125-26-352128.md) | [0.0 d](/filings/0001193125-25-277466.md) | [0.0 d](/filings/0001193125-26-108287.md) | [0.1](/filings/0001193125-26-224091.md) | [0.0 d](/filings/0001193125-26-352128.md) |
| Share repurchases | $m | [0.0 d](/filings/0000950170-23-058838.md) | [0.0 d](/filings/0000950170-24-038059.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [35.4](/filings/0000950170-23-058838.md) | [44.7](/filings/0000950170-24-056838.md) | [44.8](/filings/0000950170-24-096967.md) | [46.4](/filings/0000950170-24-127005.md) | [49.5](/filings/0000950170-25-069125.md) | [50.2](/filings/0000950170-25-107270.md) | [51.2](/filings/0001193125-25-277466.md) | [2.5](/filings/0001193125-26-224091.md) | [3.2](/filings/0001193125-26-352128.md) | [101](/filings/0001193125-25-277466.md) | [4.8](/filings/0001193125-26-224091.md) | [6.3](/filings/0001193125-26-352128.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 7,264,414 at 2026-08-12, from the cover of the [10-Q filed 2026-08-14](/filings/0001193125-26-352128.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.